Adverum Biotechnologies competitors

Zippia score 4.2

Adverum Biotechnologies main competitors are Exelixis, Iovance Biotherapeutics, and Gilead Sciences.

Competitor Summary. See how Adverum Biotechnologies compares to its main competitors:

Gilead Sciences has the most employees (11,800).
Employees at Exelixis earn more than most of the competitors, with an average yearly salary of $108,978.
The oldest company is Upsher-Smith Laboratories, founded in 1919.

Work at Adverum Biotechnologies?

Share your experience

Adverum Biotechnologies vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Adverum Biotechnologies	2006	4.2	Menlo Park, CA	2	$3.6M	188
Seagen	1997	4.7	Bothell, WA	3	$2.0B	900
Gilead Sciences	1987	4.5	Foster City, CA	9	$28.8B	11,800
Human Genome Sciences	1992	4.9	Rockville, MD	1	$131.0M	1,000
Sarepta Therapeutics	1980	4.8	Cambridge, MA	2	$1.9B	840
Exelixis	1994	4.9	Alameda, CA	1	$2.2B	484
Cubist Pharmaceuticals	1992	4.8	Lexington, MA	1	$926.4M	873
Quidel	1979	4.7	San Diego, CA	3	$1.7B	1,500
Iovance Biotherapeutics	2007	4.2	San Carlos, CA	3	$164.1M	319
GlobeImmune	1995	3.5	Louisville, CO	1	$6.5M	22
Upsher-Smith Laboratories	1919	4.7	Maple Grove, MN	4	$420.0M	550
Medivation	2003	4.8	San Francisco, CA	1	$1.0B	628
Dicerna Pharmaceuticals	2007	4.6	Cambridge, MA	3	$164.3M	302
Intercept Pharmaceuticals	2002	4.4	New York, NY	2	$285.7M	437
Regeneron	1988	4.9	Tarrytown, NY	7	$14.2B	9,123

Rate Adverum Biotechnologies' competitiveness in the market.

Adverum Biotechnologies salaries vs competitors

Among Adverum Biotechnologies competitors, employees at Exelixis earn the most with an average yearly salary of $108,978.

Compare Adverum Biotechnologies salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Adverum Biotechnologies	$90,460	$43.49	-
Seagen	$85,008	$40.87	-
Gilead Sciences	$99,828	$47.99	-
Human Genome Sciences	$70,157	$33.73	-
Sarepta Therapeutics	$94,985	$45.67	-
Exelixis	$108,978	$52.39	-

Compare Adverum Biotechnologies job title salaries vs competitors

Company	Highest salary	Hourly salary
Adverum Biotechnologies	$82,254	$39.55
Quidel	$125,654	$60.41
Exelixis	$125,007	$60.10
Sarepta Therapeutics	$118,892	$57.16
Cubist Pharmaceuticals	$115,708	$55.63
Human Genome Sciences	$110,356	$53.06
Gilead Sciences	$107,903	$51.88
Regeneron	$98,172	$47.20
Upsher-Smith Laboratories	$98,023	$47.13
Dicerna Pharmaceuticals	$90,577	$43.55
Intercept Pharmaceuticals	$88,380	$42.49
Medivation	$87,146	$41.90
Seagen	$82,544	$39.68
Iovance Biotherapeutics	$79,978	$38.45
GlobeImmune	$77,068	$37.05

Do you work at Adverum Biotechnologies?

Is Adverum Biotechnologies able to compete effectively with similar companies?

Adverum Biotechnologies jobs

Adverum Biotechnologies demographics vs competitors

Compare gender at Adverum Biotechnologies vs competitors

Job title	Male	Female
Sarepta Therapeutics	44%	56%
Cubist Pharmaceuticals	52%	48%
Regeneron	54%	46%
Gilead Sciences	56%	44%
Quidel	58%	42%
Adverum Biotechnologies	-	-

Male

Female

100%

75%

50%

25%

Adverum Biotechnologies

Quidel

Gilead Sciences

Regeneron

Cubist Pharmaceuticals

Sarepta Therapeutics

25%

50%

75%

100%

Compare race at Adverum Biotechnologies vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Gilead Sciences	44%	20%	8%	23%	6%	9.8
Quidel	50%	24%	8%	14%	5%	9.8
Regeneron	54%	15%	10%	17%	4%	9.8
Sarepta Therapeutics	66%	12%	5%	13%	4%	9.3
Cubist Pharmaceuticals	60%	12%	8%	17%	4%	9.9
Upsher-Smith Laboratories	69%	10%	8%	11%	3%	9.6

Adverum Biotechnologies revenue vs competitors

Adverum Biotechnologies revenue is $3.6M. Among it's competitors, the company with the highest revenue is Gilead Sciences, $28.8B . The company with the lowest revenue is GlobeImmune, $6.5M.

Adverum Biotechnologies and similar companies CEOs

CEOBio

Michael M. Morrissey Ph.d

Exelixis

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

Daniel O’Day

Gilead Sciences

Jerome B. Durso

Intercept Pharmaceuticals

Frederick G. Vogt

Iovance Biotherapeutics

Douglas C. Bryant

Quidel

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

Douglas S. Ingram

Sarepta Therapeutics

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.

Roger D. Dansey

Seagen

Michael Bonney

Cubist Pharmaceuticals

Andrew Witty

Human Genome Sciences

Mark Evenstad

Upsher-Smith Laboratories

Mark Evenstad is a Chief Executive Officer at Upsher Smith Laboratories. He works or has worked as President at Upsher Smith Laboratories.